Data gathered: October 14
Alternative Data for Cue Biopharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | 30 | Sign up | Sign up | Sign up |
| 4chan Mentions | 1 | Sign up | Sign up | Sign up |
| Reddit Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,376 | Sign up | Sign up | Sign up |
| Twitter Mentions | 21 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
| Price | $1.21 |
| Target Price | Sign up |
| Volume | 190,430 |
| Market Cap | $74M |
| Year Range | $0.45 - $2.55 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Cue Biopharma authorizes more sharesOctober 8 - Investing.com |
 |
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%October 7 - Yahoo |
 |
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingOctober 3 - Yahoo |
Cue Biopharma stock rallies nearly 40% on upcoming presentationsOctober 3 - Seeking Alpha |
|
 |
Point72 Asia Singapore Pte. Ltd. Makes New $66,000 Investment in Cue Biopharma, Inc. (NASDAQ:CUE)September 30 - ETF Daily News |
Cue Biopharma prices $12M stock offeringSeptember 26 - Seeking Alpha |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 2.4M | 3.5M | -1.1M | -10M | -10M | -0.200 |
| Q1 '24 | 1.5M | 4.3M | -2.8M | -12M | -13M | -0.250 |
| Q4 '23 | 1.2M | 4.7M | -3.6M | -13M | -14M | -0.290 |
| Q3 '23 | 1.8M | 3.6M | -1.8M | -11M | -11M | -0.240 |
| Q2 '23 | 1.2M | 4.2M | -3.1M | -13M | -13M | -0.290 |
Insider Transactions View All
| Suri Anish filed to buy 135,638 shares at $2.8. August 29 '23 |
| PASSERI DANIEL R filed to buy 134,578 shares at $2.9. August 16 '23 |
| Kiener Peter A filed to sell 357 shares at $3.3. March 27 '23 |
Similar companies
Read more about Cue Biopharma (CUE) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Cue Biopharma?
The Market Cap of Cue Biopharma is $74M.
What is the current stock price of Cue Biopharma?
Currently, the price of one share of Cue Biopharma stock is $1.21.
How can I analyze the CUE stock price chart for investment decisions?
The CUE stock price chart above provides a comprehensive visual representation of Cue Biopharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cue Biopharma shares. Our platform offers an up-to-date CUE stock price chart, along with technical data analysis and alternative data insights.
Does CUE offer dividends to its shareholders?
As of our latest update, Cue Biopharma (CUE) does not offer dividends to its shareholders. Investors interested in Cue Biopharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cue Biopharma?
Some of the similar stocks of Cue Biopharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.